Polaryx Therapeutics Announces FDA Grants Orphan Drug Designation for PLX-200 in GM2 Gangliosidoses
Retrieved on:
Monday, August 30, 2021
Hearing, Ganglioside, Niemann–Pick disease, Glycogen storage disease, Tay–Sachs disease, RXR, Drug development, Therapy, Lists of diseases, GM2, Gene, Lysosome, Trial of the century, Sandhoff disease, HEXB, Seizure, EB, Food, Disease, Neuron, LLM, Inflammation, Lysosomal storage disease, Board, Neurodegeneration, HEXA, Enzyme, Patient, CEO, Hexosaminidase, Apoptosis, TFEB, PPAR, FDA, Gangliosidosis, GM2 gangliosidoses, Nervous system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine
PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ --Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation for PLX-200 to treat GM2 gangliosidoses.
Key Points:
- PARAMUS, N.J., Aug. 30, 2021 /PRNewswire/ --Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation for PLX-200 to treat GM2 gangliosidoses.
- "We are very pleased to be granted Orphan Drug Designation for PLX-200 from the FDA for the treatment of GM2 gangliosidoses.
- Furthermore, this designation validates the rationale for clinical use of PLX-200 in GM2 gangliosidoses patients.
- Polaryx Therapeutics, Inc. is developing drug candidates for lysosomal storage disorders, for which there are currently no safe and patient-friendly treatment options available.